Search Drug Information, Interactions, Images, Dosage & Side Effects

Metabolic syndrome linked to greater COVID-19 severity 21 Jan 2022

Individuals with metabolic syndrome who are hospitalized for COVID-19 may have a greater risk for more severe COVID-19 disease, including an elevated risk of in-hospital mortality, acute respiratory distress syndrome (ARDS), and intensive care unit (ICU) admission, a recent prospective study showed.

Upper extremity DVT common in COVID-19 despite proper prophylaxis

21 Jan 2022

Osteoporosis drug holidays tied to small rise in hip fracture risk

21 Jan 2022

OSA severity tied to interarm SBP difference

21 Jan 2022

PSOARING trials boost potential of tapinarof for plaque psoriasis

21 Jan 2022

Osteoporosis a cause for concern in Singapore’s rapidly ageing population

21 Jan 2022

Eye-preserving therapies may do more harm than good in advanced retinoblastoma

21 Jan 2022

Risk of extrahepatic events high among NAFLD patients with severe liver scarring

21 Jan 2022

Aspirin does not cut death risk in hospitalized COVID-19 patients

20 Jan 2022

Tranexamic acid ups blood control after CABG, but aggravates perioperative myocardial infarction

20 Jan 2022

Stool biomarkers useful for predicting necrotizing enterocolitis in preemies

20 Jan 2022

Early and consistent: Breakthrough results in HFpEF similar to HFrEF 14 Jan 2022;
HFpEF represents a significant unmet need in CV medicine due to its prevalence, poor prognosis, and the absence of clinically proven therapeutic options. The EMPEROR-Preserved trial demonstrated the continuous clinical benefits in cardiorenal outcomes of empagliflozin in adults with HFpEF, which were consistent with the observations in adults with HFmrEF/ HFpEF in the EMPEROR-reduced trial. The combined results of the EMPEROR trials establish empagliflozin’s efficacy in heart failure regardless of ejection fraction – and if approved, empagliflozin would become the first and only clinically proven therapy to improve outcomes for the full spectrum of the disease. Therefore, empagliflozin offers a new hope for people living with heart failure.

Providing Patients with Fast & Effective Relief for Inflamed Sore Throat: An Introduction to the New Flurbiprofen Direct Spray

01 Jan 2022

The Role of NOAC in Pandemic Era (TREND)

07 Dec 2021

Product Highlight - Rinvoq

01 Dec 2021

Lixiana

Contents : Edoxaban tosilate

Indications/Uses : Prevention of stroke & systemic embolism in adult patients w/ nonvalvular atrial fibrillation (NVAF) w/ ≥1 risk factors eg, CHF, HTN, age ≥75 yr, DM, prior stroke or transient ischaemic attack. Treatment of deep vein thrombosis (DVT) & pulmonary embolism (PE) in adults. Prevention of recurrent DVT & PE in adults.

Cresemba

Contents : Isavuconazole

Indications/Uses : Invasive aspergillosis; mucormycosis in patients for whom amphotericin B is inappropriate.

Cabometyx

Contents : Cabozantinib

Indications/Uses : Advanced renal cell carcinoma in treatment-naive adults w/ intermediate or poor risk; adults following prior vascular endothelial growth factor-targeted therapy. Monotherapy for hepatocellular carcinoma in adults who have previously been treated w/ sorafenib.

Locoa

Contents : Esflurbiprofen

Indications/Uses : Relief of pain & inflammation associated w/ OA.

Cavsamir

Contents : Sevelamer carbonate

Indications/Uses : Control of hyperphosphataemia in adult patients receiving haemodialysis or peritoneal dialysis, or chronic kidney disease (CKD) not on dialysis w/ serum P ≥1.78 mmol/L.

Rinvoq

Contents : Upadacitinib

Indications/Uses : Monotherapy or in combination w/ methotrexate for moderate to severe active RA & active psoriatic arthritis in adult patients who have responded inadequately to or are intolerant to ≥1 disease-modifying anti-rheumatic drugs (DMARDs).